Novadaq Technologies Inc.TSX: NDQ

Novadaq Reports Financial Results For Second Quarter Of 2005

· Issued by Novadaq Technologies Inc. via CNW
TORONTO, Aug. 11 /CNW/ - Novadaq Technologies Inc. (TSX: NDQ) today
reported its results for the second quarter ended June 30, 2005. During the
quarter, Novadaq completed its initial public offering (IPO) and began trading
its shares on the Toronto Stock Exchange under the symbol "NDQ".
"The closing of our IPO solidifies our financial position and will allow
us to expedite the execution of the SPY(TM) System commercialization and the
clinical development of the OPTTX(TM) System", said Arun Menawat, President
and CEO of Novadaq Technologies Inc. "This first quarter as a public company
was a very active one. We completed a strategic launch of the SPY System to
six prominent cardiac centers. We also negotiated a North American
distribution agreement with a leading cardiovascular multi-national partner to
distribute this innovative vascular imaging technology, which in the coming
quarters will facilitate a broader launch of the SPY System."

Key Developments

-  Installed the SPY System in five strategic centers, including: The
   Cleveland Clinic Foundation, Medical City Dallas, The Methodist
   Hospital's Debakey Heart Institute, Lenox Hill and Stanford. Within
   each center, physicians have recognized the value of information the
   SPY System provides and continue to use this technology in their
   procedures. A sixth hospital was added to the list in June with the
   installation of the SPY System at the Enloe Medical Center in Chico,
   California.

-  Signed a strategic North American distribution agreement with the
   Sorin Group to accelerate the penetration of the SPY System into the
   United States cardiac surgery market. One of the key assets Sorin, a
   world leader in the development of medical technologies for cardiac
   surgery, brings to this emerging partnership is the strength of its
   relationships with cardiac surgeons and operating room teams
   throughout the United States.

-  Finalized a United States service agreement with KODAK to provide
   on-going service and maintenance for the SPY System.

-  Received a patent grant for the SPY Intra-operative Imaging device and
   procedure, a technology exclusively licensed from the National
   Research Council of Canada. The U.S. patent is titled "Method and
   Apparatus For Performing Intra-Operative Angiography".

-  Continued to advance the progress of the OPTTX System with the
   initiation of a 30 patient phase II study at Toronto Western Hospital,
   Toronto, Canada led by Patricia Harvey, MD, a leading retinal
   specialist. The study in Toronto is designed to demonstrate the
   effectiveness of the OPTTX System in improving the delivery and
   clinical outcomes of feeder vessel therapy (FVT), a known and
   medically accepted treatment for Wet AMD.

Financial Results

Revenue in 2005 Q2 was $64,057, representing an increase of $51,341, over
revenue in 2004 Q2 of $12,716. $45,600 of this increase is attributable to
increased procedural revenue generated by SPY imaging devices installed in the
United States during 2005 Q2. The SPY System received regulatory clearance in
the United States in January 2005; the first device was installed in the
United States in March 2005 and; as at June 30, 2005 there were a total of 6
SPY imaging devices installed in the United States.
Cost of sales increased by $35,264 to $41,271 in 2005 Q2 as compared to
$6,007 in 2004 Q2. Gross profit for the period increased by $16,077. As a
percentage of sales, gross margin decreased to 36% in 2005 Q2 from 53% in 2004
Q2. The decrease in gross profit percentage is attributable primarily to one
time royalties and installation costs associated with the placement of SPY
imaging devices in 2005 Q2. These costs will become less significant as the
installation base grows.
Sales and marketing expenses increased to $300,889 in 2005 Q2 from
$34,320 in 2004 Q2. The increase in sales and marketing expenses was a result
of the commercial launch of the SPY System in the United States in March 2005,
and included an increase in employee and related office and travel costs -
(approximately $90,000); market development costs - (approximately $63,000);
marketing materials and advertising - (approximately $35,000) and trade shows
costs (approximately $78,000).
Research and development expenses increased by $731,240, to $948,924 in
2005 Q2 from $217,684 in 2004 Q2. This increase related primarily to costs
incurred to design and build next generation OPTTX devices for use in clinical
trials (increase of approximately $408,000), which are currently in the
testing phase. The overall increase also reflects the addition of engineering
staff to support the design efforts, and clinical staff to plan and execute
OPTTX trials (increase of approximately $187,000); as well as a significant
increase in patent costs (increase of approximately $122,000). The increase in
patent costs relates to additional SPY and OPTTX patents filed during 2005 Q2.
General and administration expenses increased by $805,972, to $1,255,573
in 2005 Q2 from $449,601 in 2004 Q2. Approximately $738,000 of this increase
is attributable to increased stock based compensation expense which related to
647,070 employee stock options which vested in 2005 Q2, primarily as a result
of the Company's initial public offering on June 10, 2005. General and
administration employee cost also increased by $58,000 to support the United
States commercial launch of the SPY System, the Company's increased level of
research and development activity, and to add infrastructure appropriate for a
public company. Insurance and other administrative costs increased by
approximately $81,000. These increases were partially offset by a reduction in
legal fees due to the settlement of litigation in June 2004.
Depreciation expense decreased by $9,259 from 2004 Q2 to 2005 Q2 as
certain SPY imaging devices that were being used in research and development
in 2004 Q2, were converted to revenue producing assets during 2005 Q2.
Amortization of these devices was included in depreciation expense in 2004 Q2
and cost of sales in 2005 Q2. Amortization increased by $6,663 from 2004 Q2 to
2005 Q2 as a result of license payments made in the second half of 2004 which
are capitalized and amortized.
Interest income increased by $87,061 from 2004 Q2 to 2005 Q2 as a result
of the increase in cash and short term investment balances following the
financing completed in July 2004, and as a result of the further increase in
cash and short-term investment balances following the completion of the
Company's initial public offering on June 10, 2005.
Net loss increased by $1,472,216 to $2,283,999 in 2005 Q2 from $811,783
in 2004 Q2. The increase in net loss related primarily to increases in sales
and marketing expenses (approximately $267,000); research and development
expenses (approximately $731,000) and increased general and administrative
expenses (approximately $806,000, of which approximately $738,000 related to
the vesting of outstanding stock options following the completion of the
Company's initial public offering), and was partially offset by increased
foreign exchange gains (approximately $225,000), and increased interest income
(approximately $87,000).
On June 30, 2005 the Company had cash, cash equivalents and short-term
investments totaling $26.7 million compared to $9.4 million at December 31,
2004. On June 10th, 2005 the Company completed an initial public offering for
total gross proceeds of approximately $20.1 million.
The number of common shares outstanding as of June 30, 2005 was
17,984,950 common shares.

Conference call

Novadaq will host a conference call on Friday, August 12, 2005 at
10:00 a.m. ET to discuss its second quarter 2005 results. To access the
conference call by telephone, dial 1-800-240-5318. Please connect
approximately ten minutes prior to the beginning of the call to ensure
participation. The conference call will be archived for replay until
August 19, 2005 at midnight. To access the archived conference call, dial  
416-640-1917 or 1-877-289-8525 enter the reservation number 21132810 followed
by the number sign.

About Novadaq Technologies

Novadaq(TM) Technologies (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular and ophthalmic diseases and conditions. Novadaq's
SPY System enables surgeons to visually assess coronary vasculature and bypass
graft functionality during the course of CABG surgery. Novadaq's ophthalmic
product, OPTTX(TM) System, is aimed at the diagnosis, evaluation and treatment
of Wet Age Related Macular Degeneration (AMD) by using the same core imaging
technology that is used in the SPY. The OPTTX System is currently being
evaluated in clinical trials.
For more information, please visit the company's website at
www.novadaq.com.

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

Summary financial statements attached:
For complete financial statements please go to www.sedar.com

<<

                      NOVADAQ TECHNOLOGIES INC.
                Incorporated under the laws of Canada

                           BALANCE SHEETS
                        (expressed in U.S.$)
                              Unaudited

                                                    As at       As at
                                                   June 30,  December 31,
                                                    2005        2004
                                                      $           $
-------------------------------------------------------------------------

                              ASSETS
Current
Cash and cash equivalents                          157,269       434,380
Short-term investments                          26,567,149     8,963,894
Accounts receivable                                 57,179     1,082,659
Investment tax credits receivable                   39,236        54,468
Prepaid expenses and other receivables             420,854        58,644
Inventory                                           74,581        65,529
-------------------------------------------------------------------------
Total current assets                            27,316,268    10,659,574
-------------------------------------------------------------------------
Property, plant and equipment, net                 125,861        41,542
Deferred charges                                    15,137        19,015
Licenses, net                                    3,249,655     3,336,618
-------------------------------------------------------------------------
                                                30,706,921    14,056,749
-------------------------------------------------------------------------
-------------------------------------------------------------------------

              LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Accounts payable and accrued liabilities         1,319,014       478,692
Current portion of deferred revenue                 54,852        37,286
-------------------------------------------------------------------------
Total current liabilities                        1,373,866       515,978
-------------------------------------------------------------------------
Deferred revenue                                    40,464        59,206
-------------------------------------------------------------------------
Total liabilities                                1,414,330       575,184
-------------------------------------------------------------------------

Shareholders' equity
Share capital                                   46,213,640    27,966,017
Contributed surplus                              3,349,831     2,280,891
Deficit                                        (20,270,880)  (16,765,343)
-------------------------------------------------------------------------
Total shareholders' equity                      29,292,591    13,481,565
-------------------------------------------------------------------------
                                                30,706,921    14,056,749
-------------------------------------------------------------------------
-------------------------------------------------------------------------



                      NOVADAQ TECHNOLOGIES INC.

                   STATEMENTS OF LOSS AND DEFICIT
                        (expressed in U.S.$)
                              Unaudited


                          Three months ended           Six months ended
                               June 30,                    June 30,
                          2005          2004          2005          2004
                            $             $             $             $
-------------------------------------------------------------------------

Revenue                 64,057        12,716       219,475        36,663
Cost of sales           41,271         6,007        77,570        23,159
-------------------------------------------------------------------------
Gross profit            22,786         6,709       141,905        13,504
-------------------------------------------------------------------------

Operating expenses
Sales and marketing    300,889        34,320       402,621        81,543
Research and
 development           948,924       217,684     1,667,573       573,483
General and
 administration      1,255,573       449,601     1,689,146       837,631
Depreciation             3,702        12,961        11,968        29,875
Amortization           106,680       100,017       211,963       200,033
Loss (gain) on
 foreign exchange     (218,829)        7,002      (211,354)        3,345
-------------------------------------------------------------------------
                     2,396,938       821,584     3,771,917     1,725,910
-------------------------------------------------------------------------
Loss before the
 following          (2,374,152)     (814,875)   (3,630,012)   (1,712,406)
Interest income         90,153         3,092       124,475         3,902
-------------------------------------------------------------------------
Net loss for the
 year               (2,283,999)     (811,783)   (3,505,537)   (1,709,314)

Deficit, beginning
 of year           (17,986,881)  (14,890,009)  (16,765,343)  (13,992,478)
-------------------------------------------------------------------------
Deficit, end
 of year           (20,270,880)  (15,701,792)  (20,270,880)  (15,701,792)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Basic and fully
 diluted loss
 per share               (0.14)        (0.06)        (0.23)        (0.14)
-------------------------------------------------------------------------
-------------------------------------------------------------------------



                      NOVADAQ TECHNOLOGIES INC.

                      STATEMENTS OF CASH FLOWS
                        (expressed in U.S.$)
                              Unaudited


                          Three months ended           Six months ended
                               June 30,                    June 30,
                          2005          2004          2005          2004
                            $             $             $             $
-------------------------------------------------------------------------

OPERATING ACTIVITIES
Net loss for
 the period         (2,283,999)     (811,783)   (3,505,537)   (1,709,314)
Add (deduct) items
 not involving cash
  Depreciation and
   amortization         18,421       119,916       235,307       240,184
  Stock based
   compensation        908,331       170,000     1,068,940       340,000
-------------------------------------------------------------------------
                    (1,257,247)     (521,867)   (2,201,290)   (1,129,130)
Net change in
 non-cash working
 capital balances
 related to
 operations            307,541       (55,310)    1,507,474       102,624
-------------------------------------------------------------------------
Cash (used) in
 operating activities (949,706)     (577,176)     (693,816)   (1,026,506)
-------------------------------------------------------------------------

FINANCING ACTIVITIES
Issuance of common
 shares             18,247,623             -    18,247,623             -
-------------------------------------------------------------------------
Cash provided by
 financing
 activities         18,247,623             -    18,247,623             -
-------------------------------------------------------------------------

INVESTING ACTIVITIES
Purchase of
 property, plant
 and equipment         (89,566)            -      (102,663)      (31,068)
Purchase of licenses  (125,000)            -      (125,000)            -
Investments in
 short-term
 investments, net  (17,541,464)      542,839   (17,603,255)      999,625
-------------------------------------------------------------------------
Cash provided by
 (used in)
 investing         (17,756,030)      542,839   (17,830,918)      968,557
-------------------------------------------------------------------------

Net increase
 (decrease) in
 cash and cash
 equivalents
 during the period    (458,113)      (34,337)     (277,111)      (57,951)
Cash and cash
 equivalents,
 beginning of period   615,382       124,178       434,380       147,790
-------------------------------------------------------------------------
Cash and cash
 equivalents,
 end of period         157,269        89,841       157,269        89,841
-------------------------------------------------------------------------
-------------------------------------------------------------------------
>>
%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases